Agios Pharmaceuticals | AGIO - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
AbbVie USD 10.27B 1000K 2026-06
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
Alnylam Pharmaceuticals USD 1.06B 160.97M 2026-06
Amgen USD 11.69B 6.9B 2026-06
Arrowhead Research USD 245.35M 30.35M 2026-06
Astellas Pharma JPY 455.56B 33.8B 2026-06
AstraZeneca USD 12.22B 4.04B 2026-06
Bayer EUR 10.04B 168M 2026-06
Biogen USD 2.98B 1.02B 2026-06
BioMarin Pharmaceutical USD 6.32B 5.69B 2026-06
Bristol-Myers Squibb USD 22.32B 2.25B 2026-06
Daiichi Sankyo JPY 489.64B 21.08B 2026-06
Eli Lilly USD 10.52B 496M 2026-06
Exelixis USD 380.28M 20.8M 2026-06
Gilead Sciences USD 3.95B 19.57B 2026-06
GlaxoSmithKline GBP 5.8B 468M 2026-06
Incyte USD 973.64M 4.65B 2026-06
Ionis Pharmaceuticals USD 370.24M 6.24M 2026-06
Merck USD 15.77B 2.4B 2026-06
Moderna USD 960M 817M 2026-06
Nektar Therapeutics USD 49.12M 8.22M 2026-03
Novartis USD 10.2B 912M 2026-06
Novartis USD 9.29B 507M 2026-03
Pfizer USD 85.19B 4.91B 2026-06
Puma Biotechnology USD 49.26M 3.2M 2024-06
Regeneron Pharmaceuticals USD 31.71B 287.8M 2026-06
Roche Holding CHF 18.9B 2.12B 2026-06
Sarepta Therapeutics USD 387.96M 15.59M 2026-06
Vertex Pharmaceuticals USD 2.07B 217.1M 2026-06